Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.


All conventional front-of-the-eye therapies are administered using 100-year-old legacy eye-dropper pipette technology, consistently overdosing the eye with 30-50 μL of often toxic preservatives and pharmaceutical ingredients compared to the eye’s natural, physiologic tear film capacity of 7-8 μL. This overdose is associated with many ocular side effects such as hyperemia, redness, discomfort, foreign body sensation, pigment discoloration, periorbital dermatitis and others. For some topical medications, there are also major cardiovascular side effects such as bradycardia and arrhythmia. High precision micro-dosing delivers physiologic doses of 6-8 μL in a targeted way, directly coating the corneal surface rather than the conjunctiva thus reducing collateral tissue exposure and focusing on the cornea where 80% of intraocular drug penetration occurs. Microtherapeutics reduce 75-80% of the drug exposure to minimize toxicity leading to gentler, safer treatments. In addition, Eyenovia’s smart electronics and mobile e-health technology will transform compliance and chronic disease management by empowering patients and physicians for the first time with access to dynamic, real time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm. Eyenovia has three late-stage micro-therapeutic programs in glaucoma, mydriasis and dry eye. Eyenovia is expected to complete all three development programs through registration by 2020.